



(79) - (105)

العدد الثالث

والأربعون

أنماط جينات *PPARG* و *IRS1* و *TCF7L2* و *KCNJ11* لدى الأفراد البدنيين المصابين

بالسكري وغير المصابين بالسكري

م.د. زينب ضياء جبوري الخطيب

قسم علوم الحياة / كلية العلوم / جامعة واسط

zalkhateeb@uowasit.edu.iq

المستخلص:

البدانة حالة معقدة متعددة العوامل تتأثر بعوامل بيئية وجينية، مما يؤدي إلى مضاعفات متنوعة مثل داء السكري من النوع الثاني. ومع ذلك، فإن التباينات الظاهرية تزيد من الاهتمام بدور التعددات الجينية في تعديل قابلية الإصابة بداء السكري من النوع الثاني لدى الأفراد المصابين بالبدانة. هدفت الدراسة الحالية الى تقصي التعبير الجيني والمخاطر المرتبطة بجينات *IRS1* و *KCNJ11* و *PPARG* و *TCF7L2* على المستوى الجزيئي لدى الأفراد البدنيين، سواء كانوا مصابين بداء السكري من النوع الثاني (OT2DM) أو غير مصابين به (OND). اجمالاً، تم اختيار ٩٠ شخصاً بدينياً، ٤٥ مصاباً بداء السكري من النوع الثاني و ٤٥ غير مصابين به، حيث تم خضوعهم الى سحب عينات الدم الوريدي لغرض فحصه باستعمال الاختبارات الجزيئية والمصلية. استُخدم التنميط الجيني الجزيئي بتقنية تفاعل البوليميراز المتسلسل النوعي للأليلات مع تحليل تعدد أطوال قطع التقييد (PCR-RFLP) لتحديد النمط الجيني rs1801278 لجين *IRS1*، بينما استخدمت تقنية تفاعل البوليميراز المتسلسل T-ARMS لتحديد النمط الجيني rs5219 لجين *KCNJ11*، و rs1801282 لجين *PPARG*، و rs7903146 لجين *TCF7L2*. أظهرت النتائج أن التباين الجيني (*IRS1* G>A) (rs1801278) مرتبط ارتباطاً وثيقاً بداء السكري من النوع الثاني لدى الأفراد البدنيين، كما وُجد أن النمطين الجينيين GA و AA هما الأكثر شيوعاً لدى الأفراد البدنيين المصابين بالسكري من النوع الثاني مقارنةً بالأفراد غير المصابين به. بالإضافة إلى ذلك،



لوحظ ارتفاع ملحوظ في تكرار ونسبة الخطر في الأليل A لدى الأفراد المصابين بالسكري من النوع الثاني مقارنةً بالأليل G. ما يخص جين (*KCNJ11* C>T (rs5219)، كان تكرار النمط الجيني CT ومخاطره أعلى بكثير من النمطين CC و TT لدى الأفراد المصابين بداء السكري من النوع الثاني، وكذلك مقارنةً بالأنماط الجينية لدى الأفراد غير المصابين به. وبصورة مماثلة، كان تردد الأليل T ومخاطره أعلى من تردد الأليل C ومخاطره لدى الأفراد المصابين بداء السكري من النوع الثاني. أما بالنسبة لجين (*PPARG* G>C (rs1801282)، فقد كانت نسبة النمطين الجينيين GC و CC ومخاطرها أعلى بكثير من النمط الجيني GG لدى الأفراد المصابين بداء السكري، وكذلك مقارنةً بالنمط الجيني GC لدى الأفراد غير المصابين بداء السكري. وأظهرت نتائج تردد الأليلات ارتفاعاً ملحوظاً في وجود الأليل C ومخاطره مقارنةً بالأليل G لدى الأفراد المصابين بداء السكري من النوع الثاني، وكذلك مقارنةً بالأليلين G و C لدى الأفراد غير المصابين بداء السكري من النوع الثاني. أظهرت نتائج تحليل الطفرة الجينية (*TCF7L2* C>T (-rs7903146) أن تردد النمطين الجينيين CT و TT ومخاطرها في الأفراد البدينين والمصابين بالسكري من النوع الثاني كان أعلى بكثير مما هو عليه في الأفراد البدينين غير المصابين بالسكري؛ بينما كانت نسبة الأليل T ومخاطره في مرضى السكري من النوع الثاني أعلى بشكل ملحوظ من الأليل C. من هنا، استنتجت هذه الدراسة إلى انتشار الطفرات الجينية (*IRS1* G>A (rs1801278)، و (*KCNJ11* C>T (rs5219)، و (*PPARG* G>C (rs1801282)، و (*TCF7L2* C>T (-rs7903146) وارتفاع خطرهما لدى مرضى السكري من النوع الثاني المصابين بالبدانة مما يستدعي إجراء المزيد من الدراسات للتحقق من أدوار الجينات المختلفة وإمكانية استخدامها في تشخيص مثل هذه الاضطرابات الأيضية.

الكلمات المفتاحية: rs1801278، rs5219، rs1801282، و rs7903146، السكري من النوع الثاني، العراق.



Patterns of *PPARG*, *IRS1*, *TCF7L2*, and *KCNJ11* Genes in Obese Diabetic and Non-Diabetic Individuals

Lecturer Doctor Zainab Dhiyaa Jabuori Alkhateeb

Department of Biology / College of Science / University of Wasit

zalkhateeb@uowasit.edu.iq

Abstract:

Obesity is a complex multifactorial condition influenced by both environmental and genetic factors, resulting in various complications such as type 2 diabetes mellitus (T2DM). However, phenotypic variations lead to increasing the interest about the role of genetic polymorphisms in modulating susceptibility to T2DM among obese individuals. This study aims to molecularly identify the expression and risks of *IRS1*, *KCNJ11*, *PPARG* and *TCF7L2* genes among the obese individuals who have the T2DM (OT2DM) and non-diabetic (OND) with investigation of the levels of lipid profiles and relationship to some demographic risk data. **Materials and methods:** Totally, 90 individuals (45 OT2DM and 45 OND) were selected and subjected to collection of venous blood that was examined molecularly and serologically. Molecular genotyping using allele-specific PCR-RFLP was used for SNPs targeting rs1801278 for *IRS1* while T-ARMS PCR was used for SNPs targeting rs5219 for *KCNJ11*, rs1801282 for *PPARG*, and rs7903146 for *TCF7L2* genes. The findings of *IRS1* G>A (rs1801278) revealed a marked elevation in frequency and risk of GA and AA genotypes of OT2DM individuals when compared to OND population. In OT2DM, there was a significant higher frequency and risk of A allele than G allele. Regarding *KCNJ11* C>T (rs5219), the frequency and risk of CT genotype was apparently higher than the CC and TT in OT2DM than OND. Subsequently, the OT2DM was reported a higher frequency and risk of T



allele than C allele. Concerning *PPARG* G>C (rs1801282), values of frequency and risk of GC and CC genotypes were elevated more than the GG genotype among the OT2DM population; whereas, results of allele frequency in OT2DP were detected a marked elevation in existence and risk of C allele in comparison to G allele. Relation *TCF7L2* C>T (-rs7903146), our findings identified that the frequency and risk of CT and TT genotypes in OT2DM population was significantly higher than OND. Subsequently, the percentage and risks of T allele in OT2MD population was markedly higher the C allele. In conclusion, this study indicates the predominant and risk of *IRS1* G>A (rs1801278), *KCNJ11* C>T (rs5219), *PPARG* G>C (rs1801282), and *TCF7L2* C>T (-rs7903146) in OT2DM compared to OND suggesting importance of furthermore studies to investigate the roles of various genes in OT2DM, and possible utilization of such genes in determination of such metabolic disorders.

Keywords: rs1801278, rs5219, rs1801282, and rs7903146, Gene polymorphism, Iraq

Introduction

Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterised by persistent hyperglycaemia due to impaired insulin production or insulin resistance or both (Al-Shaeli et al., 2022). T2DM is an increasingly critical health challenge in the world today and, with the shift in lifestyle, urbanization and increasing obesity prevalence, along with genetic susceptibility, is playing an increasingly important role in determining individual susceptibility (Chandrasekaran and Weiskirchen, 2024; Rob et al., 2025). The last decades, the importance of specific molecular genetic variations that are associated with glucose homeostasis, insulin signaling and pancreatic β -cell function was highlighted (Sami et al., 2025). There are several genes have been extensively studied with strong association to T2DM risk such as *insulin receptor substrate 1 (IRS1)*, *potassium inwardly rectifying channel subfamily J member 11 (KCNJ11)*, *peroxisome*



proliferator-activated receptor gamma (PPARG), and *transcription factor 7-like 2 (TCF7L2)*, (Blanken et al., 2025; Rana et al., 2026).

The *IRS1* is a key cytoplasmic adapter protein that located on the chromosome 2q36 and widely expressed in insulin-sensitive tissues such as skeletal muscle, adipose tissue and liver (Szablewski, 2024). Upon insulin binding to its receptor, the receptor undergoes auto-phosphorylation and subsequently phosphorylates *IRS1* on specific tyrosine residues to create docking sites for various signaling molecules and influencing the glycogen synthesis, lipid metabolism and protein synthesis (Haider, 2023; Kumar, 2024).

KCNJ11 gene, which encodes the Kir6.2 protein, forms an essential part of the ATP-sensitive potassium (KATP) channel that is fundamental to the linking of the cellular metabolism to insulin secretion in pancreatic β -cells (Yang and Yang, 2025). The KATP channels are left open in low glucose conditions and the potassium ions move out of β -cells through maintaining the cell in a hyperpolarized state, and inhibition of insulin release (Merrins and Kibbey, 2024). During high blood glucose, the enhanced intracellular production of ATP closes the KATP channels and subsequent depolarization of the membrane, which causes an opening of voltage-dependent calcium channels, and stimulates the secretion of insulin (Oluwamodupe and Babalola, 2024).

As a key point of control in adipogenesis and lipid metabolism, the *PPARG* is a ligand-activated transcription factor, a nuclear hormone receptor (Yang et al., 2024). *PPARG* gene is among the significant genes that involved in pathogenesis of obesity and T2DM. This gene, located on chromosome 3p25, is largely expressed in adipose tissue with other genes, to regulate and express the adipocyte differentiation and fat storage (Veerabathiran et al., 2023; Dracheva et al., 2024). Moreover, *PPARG* gene plays an important role in insulin sensitivity, which is reflected in a reduced lipo-toxicity in insulin-sensitive tissues like liver and skeletal muscle, thereby enhancing insulin action, while promoting the storage of free fatty acids in adipocytes. This re-distribution of lipids enhances the uptake and use of glucose,



glycemic control, and reducing the risk of insulin resistance (Giannopoulos et al., 2023; Jo, 2024; Singh et al., 2026).

TCF7L2 is a regulatory gene on chromosome 10q25.2-q25.3 that encodes a transcription factor, which is a central component of the Wnt/ β -catenin signaling pathways involved in metabolic homeostasis as well as regulation of cell proliferation, differentiation and gene expression (Adeerjiang et al., 2025; Pati et al., 2025; Salamah et al., 2026). The functions of *TCF7L2* are done by binding to β -catenin and regulating the transcription of target genes involved in glucose production and insulin secretion; while in pancreatic β -cell and liver, it influences the biosynthesis and secretion of insulin and gluconeogenesis, respectively (Tian et al., 2024; Younus and Al-Faisal, 2024).

In Iraq, several studies have been conducted in last 10 years to investigate the role of *IRS1*, *KCNJ11*, *PPARG*, and *TCF7L2* genes solely among various diseased patients (Baquer and Shwan, 2023; Younus and Al-Faisal, 2024; Nasr et al., 2024; Mudhaffer and Hassan, 2025). Hence, this research aims to Molecular exploring the expression and risks of *IRS1*, *KCNJ11*, *PPARG* and *TCF7L2* genes among the T2DM and non-diabetic obese individuals.

Materials and methods

Samples and data

The present study was compromised an overall 90 obese individuals [45 T2DM (OT2DM) and 45 non-diabetes (OND)] who attended to a number of private clinician specialist in Al-Kut city during January (2026). Under aseptic conditions, 5ml of venous blood was drained from each individual, and divided equally into free-anticoagulant glass gel tube for serum obtaining as well as into an anticoagulant plastic tube (whole blood) for molecular testing. After centrifugation, the serum and whole blood samples were kept frozen (-20C) until be tested. Additionally, information concerning the age and sex of study population was reported as a risk factor.



Molecular genotyping

After preparation at room temperature, the gSYNC™ DNA Extraction Kit (Genaid, Taiwan) was served to extract DNAs from the whole blood samples under restricted conditions. For preparation of Mastermix tubes, all samples of DNAs were genotyped using allele-specific PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) was served for SNPs targeting rs1801278 for *IRS1* gene while T-ARMS PCR (Tetra-primer Amplification Refractory Mutation System) was utilized for SNPs targeting rs5219 for *KCNJ11*, rs1801282 for *PPARG*, and rs7903146 for *TCF7L2* genes (Table 1), and Promega GoTaq™ G2 Green Master Mix Kit [Promega, Korea (Cat. No.PRM7822)]. The PCR mixtures prepared at a final volume of 20μL, were amplified in the Thermal Cycler under a modified condition (Table 2). The PCR-RFLP products were digested overnight with restriction enzyme (PstI restriction endonuclease), resolved by electrophoresis on Agarose-gel (2%) stained with Ethidium bromide at 100volt and 80mA for 90min, and visualized with the UV-transilluminator.



Table (1): Sequences of primers utilized for SNPs detection for study genes

Reference	Product size	Primer sequence (5'-3')		Gene
Albegali <i>et al.</i> (2019)	221bp	CTTTCCACAGCTCACCTT	F (G allele)	<i>IRS1</i>
		GTTAGGCCTGCAAATGTCT	R (A allele)	
Reddy <i>et al.</i> (2021)	349bp	ATGAGCCACCAGGCCATGG CGAAGAG	F:Outer	<i>KCNJ11</i>
		AGTGAGGCCCTAGGCCACG TCCGAGG	R:Outer	
	162bp	CTGGCGGGCACGGTACCTG GGATC	F:Inner (C allele)	
	237bp	GACACGCCTGGCAGAGGAC CCTGACA	R:Inner (T allele)	
Baqer and Shwan (2023)	453bp	CTCCTAATAGGACAGTGCC AGCCA	F:Outer	<i>PPARG</i>
		TTTAAATGAACGCGATAGC AACGAG	R:Outer	
	238bp	GAAACTCTGGGAGATTCTC CTATTGTCC	F:Inner (C allele)	
	267bp	ATCAGTGAAGGAATCGCTT TCAGC	R:Inner (G allele)	
Abdullah and Ali (2022)	429bp	TTTTTCACATGTGAAGACA TACAC	F:Outer	<i>TCF7L2</i>
		TTTATAGCGAAGAGATGAA ATGTA	R:Outer	
	212bp	ATTAGAGAGCTAAGCACTT TTTAGAGA	F:Inner (C allele)	
	269bp	CTCATACGGCAATTAAATT ATAGAG	R:Inner (T allele)	



Table (2): Conditions of Thermal Cycler system for PCR mixture of study genes

Gene				Condition
<i>TCF7L2</i>	<i>PPARG</i>	<i>KCNJ11</i>	<i>IRS1</i>	
1 Cycle (95°C for 5min)	1 Cycle (95°C for 5min)	1 Cycle (95°C for 5min)	1 Cycle (95°C for 5min)	Initial denaturati on
35 Cycles (95°C for 30sec)	40 Cycles (95°C for 30sec)	35 Cycles (95°C for 30sec)	35 Cycles (95°C for 30sec)	Denaturati on
(62°C for 30sec)	(61°C for 1min)	(61°C for 1min)	(62°C for 30sec)	Annealing
(72°C for 30sec)	(72°C for 45sec)	(72°C for 45sec)	(72°C for 30sec)	Extension
(72°C for 5min)	(72°C for 5min)	(72°C for 5min)	(72°C for 5min)	Final extension
4°C (Forever)	4°C (Forever)	4°C (Forever)	4°C (Forever)	Hold

Statistical analysis

All calculations were done with chi-square (χ^2), one-way ANOVA and 95% confidence interval (95%CI) using the GraphPad Prism software; odds ratio (OR), relative risk (RR) and number needed to treat (NNT) were calculated with the MedCalc statistical software. The frequency of the genotypes and alleles among the study populations is significantly different at $p < 0.05$ (Gharban et al., 2024).

Results

IRS1-rs1801278G>A polymorphism

In OT2DM individuals, the findings shown a significant increase ($p < 0.05$) in frequency of GA (65.52%) and AA (83.33%) genotypes with a significant decrease in GG genotype (38.18%) when compared to OND population (34.48%, 16.67%, and 61.82%, respectively). Subsequently, the risk of GA



and AA genotypes in OT2DM were markedly ($p < 0.0001$) higher than OND individuals (Tables 1, 2).

Table (1): Genotype frequency of *IRS1*-rs1801278 G>A among the OT2DM and OND populations

95%CI	p-value	OND	OT2DM	Total	Genotype
100.2 to 200.2	0.0363	34 (61.82%)	21 (38.18%)	55	GG
147.2 to 247.2	0.0214	10 (34.48%)	19 (65.52%)	29	GA
373.5 to 473.5	0.0013	1 (16.67%)	5 (83.33%)	6	AA
-	-	0.0402	0.0144	p-value	
-	-	18.84 to 94.15	5.849 to 118.8	95%CI	

Table (2): Risk of genotype frequency of *IRS1*-rs1801278G>A among the OT2DM and OND populations

95%CI	NNT	RR	OR	OND	OT2DM	Total	Genotype
35.290 (Harm) to ∞ to 3.457 (Benefit)	7.665 (Benefit)	0.6793	0.2831	34	21	55	GG
3.812 (Harm) to ∞ to 14.634 (Benefit)	10.311 (Harm)	1.3245	2.5577	10	19	29	GA
2.371 (Harm) to ∞ to 6.335 (Benefit)	7.578 (Harm)	1.4091	5.5	1	5	6	AA
-	-	0.0001	0.0001	p-value			
-	-	0.146	3.717	95%CI			



		to 2.129	to 9.278	
--	--	-------------	-------------	--

Additionally, though the frequency of G allele was differed insignificantly ($p < .0702$) between OT2DM (47.62%) and OND (52.38%) populations, significant higher frequency ($p < 0.0334$) of A allele (68.57%) was observed in OT2DM when compared to those of OND (52.38% and 31.43%, respectively). Also, the risk (OR, RR) of A allele in OT2DM (2.4, 1.2610) was significantly higher ($p < 0.0001$) than G allele (0.4167, 0.7930), (Tables 3, 4).

Table (3): Allele frequency of *IRS1*-rs1801278G>A among the OT2DM and OND populations

95%CI	p-value	OND	OT2DM	Total	Allele
-19.76 to 80.24	0.0702	44 (52.38%)	40 (47.62%)	84	G
186.0 to 286.0	0.0334	11 (31.43%)	24 (68.57%)	35	A
-	-	0.0455	0.0442	p-value	
-	-	91.19 to 175.0	75.00 to 191.2	95%CI	

Table (4): Risk of Allele frequency of *IRS1*-rs1801278G>A among the OT2DM and OND populations

95%CI	NNT	RR	OR	OND	OT2DM	Total	Allele
15.842 (Harm) to ∞ to 4.319 (Benefit)	11.877 (Benefit)	0.7930	0.4167	44	40	84	G
4.319 (Harm) to ∞ to 15.842 (Benefit)	11.877 (Harm)	1.2610	2.4	11	24	35	A
-	-	0.0001	0.0001	p-value			
-	-	1.946	11.19	95%CI			



		to 4	to 14.01	
--	--	------	-------------	--

***KCNJ11*- rs5219C>T polymorphism**

In *KCNJ11* gene, the frequency of CT genotype (70%) was significantly higher ($p < 0.05$) than the CC (36.54%) and TT (62.5%) in OT2DM individuals as well as genotypes of OND population; CC (63.46%), CT (30%) and TT (37.5%). Subsequently, the risk (OR, RR) of CT genotype (3.5, 1.4412) was apparently ($p < 0.0001$) higher than those of CC (0.2657, 0.6587) and TT (1.7500, 1.1731) genotypes in individuals of T2DM (Tables 5, 6). Also, the frequency and risk of T allele (68.42%, 2.275, 1.2391) was significantly ($p < 0.05$) higher than those of C allele (48.78%, 0.4396, 0.8071) in OT2DM individuals (Tables 7, 8).

Table (5): Genotype frequency of *KCNJ11*-rs5219C>T in OT2DM and OND populations

95%CI	p-value	OND	OT2DM	Total	Genotype
121.0 to 221.1	0.0343	33 (63.46%)	19 (36.54%)	52	CC
204.1 to 304.1	0.0268	9 (30%)	21 (70%)	30	CT
108.8 to 208.8	0.0341	3 (37.5%)	5 (62.5%)	8	TT
-	-	0.0111	0.0201	p-value	
-	-	0.0363 to 87.27	12.73 to 99.96	95%CI	

Table (6): Risk of *KCNJ11*-rs5219C>T in OT2DM and OND populations

95%CI	NNT	RR	OR	OND	OT2DM	Total	Genotype
52.95 (Harm) to ∞ to 3.376 (Benefit)	7.213 (Benefit)	0.6587	0.2657	33	19	52	CC
3.464 (Harm) to	7.933 (Harm)	1.4412	3.5	9	21	30	CT



∞ to 27.335 (Benefit)							
3.066 (Harm) to ∞ to 4.703 (Benefit)	17.622	1.1731	1.7500	3	5	8	TT
-	-	0.0001	0.0001	p-value			
-	-	0.1032	5.194	95%CI			
		to 2.079	to 10.79				

Table (7): Allele frequency of *KCNJ11*-rs5219C>T in OT2DM and OND populations

95%CI	p-value	OND	OT2DM	Total	Allele
-34.50 to 65.50	0.0855	42 (51.22%)	40 (48.78%)	82	C
184.0 to 284.0	0.0331	12 (31.58%)	26 (68.42%)	38	T
-	-	0.0362	0.0405	p-value	
-	-	83.37 to 166.2	66.17 to 183.4	95%CI	

Table (8): Risk of Allele frequency of *KCNJ11*-rs5219C>T in OT2DM and OND populations

95%CI	NNT	RR	OR	OND	OT2DM	Total	Allele
15.17 (Harm) to ∞ to 4.491 (Benefit)	12.758 (Benefit)	0.8071	0.4396	42	40	82	C
4.491 (Harm) to ∞ to 15.17 (Benefit)	12.758 (Harm)	1.2391	2.275	12	26	38	T
-	-	0.0001	0.0001	p-value			



-	-	1.721 to 3.768	10.3 to 13.02	95%CI
---	---	----------------------	------------------	-------

***PPARG*-rs1801282 G>C polymorphism**

The findings of *PPARG* gene polymorphism were revealed a significant increases ($p < 0.05$) in percentage of GC (61.11%) and CC (66.67%) genotypes when compare to GG genotype (37.78%) in the OT2DM population as well as to those of GC (38.89%) of OND individuals. However, the risks (OR, RR) of GC genotype (2.1180, 1.2699) followed by CC genotype (2.1538, 1.2308) in OT2DM population were significantly ($p < 0.0001$) higher than identified in GG genotype (0.3686, 0.7149) of OT2DM population (Tables 9, 10). For allele frequency, the results were showed a significant elevation ($p < 0.05$, $p < 0.0001$) in existence and risk of C allele (62.22%, 1.7738, 1.1336) in comparison with those detected in G allele (48.15%, 0.5638, 0.8473) of OT2DP population as well as when compared to the results of the OND individuals, G (51.85%) and C (37.78%) alleles (Tables 11, 12)

Table (9): Genotype frequency of *PPARG*-rs1801282 G>C in OT2DM and OND populations

95%CI	p-value	OND	OT2DM	Total	Genotype
105.3 to 205.3	0.0353	28 (62.22%)	17 (37.78%)	45	GG
91.17 to 191.2	0.0371	14 (38.89%)	22 (61.11%)	36	GC
161.8 to 261.8	0.0306	3 (33.33%)	6 (66.67%)	9	CC
-	-	0.0369	0.0212	p-value	
-	-	6.734 to 82.89	17.11 to 93.27	95%CI	

Table (10): Risk of genotype frequency of *PPARG*-rs1801282 G>C in OT2DM and OND populations



95%CI	NNT	RR	OR	OND	OT2DM	Total	Genotype
20.352 (Harm) to ∞ to 3.733 (Benefit)	9.143	0.7149	0.3686	28	17	45	GG
4.155 (Harm) to ∞ to 12.586 (Benefit)	12.406 (Harm)	1.2699	2.1180	14	22	36	GC
3.051 (Harm) to ∞ to 5.627 (Benefit)	13.333 (Harm)	1.2308	2.1538	3	6	9	CC
-	-	0.0001	0.0001	p-value			
-	-	0.3024 to 1.841	0.9883 to 4.082	95%CI			

Table (11): Allele frequency of *PPARG*-rs1801282G>C in OT2DM and OND populations

95%CI	p-value	OND	OT2DM	Total	Allele
-26.49 to 73.51	0.0775	42 (51.85%)	39 (48.15%)	81	G
105.3 to 205.3	0.0353	17 (37.78%)	28 (62.22%)	45	C
-	-	0.021	0.0203	p-value	
-	-	44.57 to 134.2	34.20 to 144.6	95%CI	

Table (12): Risk of Allele frequency of *PPARG*-rs1801282G>C in OT2DM and OND populations

95%CI	NNT	RR	OR	OND	OT2DM	Total	Allele
-------	-----	----	----	-----	-------	-------	--------



12.548 (Harm) to ∞ to 5.081 (Benefit)	17.076 (Benefit)	0.8473	0.5638	42	39	81	G
5.569 (Harm) to ∞ to 10.784 (Benefit)	23.03 (Harm)	1.1336	1.7738	17	28	45	C
-	-	0.0001	0.0001	p-value			
-	-	0.8284 to 2.809	6.518 to 8.856	95%CI			

***TCF7L2*-rs7903146 C>T polymorphism**

The polymorphism results of the *TCF7L2* gene identified that the frequency of CT (64.1%) and TT (66.67%) genotypes in OT2DM population was significantly higher ($p < 0.05$) than detected in OND (35.9% and 33.33%, respectively); whereas, frequency rate of CC genotype was reduced significantly ($p < 0.0431$) in OT2MD population (35.56%) compared to those of OND individuals (64.44%), (Tables 12, 13).

Table (12): Genotype frequency of *TCF7L2*-rs7903146C>T among the OT2DM and OND populations

95%CI	p-value	OND	OT2DM	Total	Genotype
133.5 to 233.5	0.0431	29 (64.44%)	16 (35.56%)	45	CC
129.2 to 229.2	0.0435	14 (35.9%)	25 (64.1%)	39	CT
161.8 to 261.8	0.0301	2 (33.33%)	4 (66.67%)	6	TT
-	-	0.0466	0.0308	p-value	
-	-	1.662 to 87.45	12.55 to 98.34	95%CI	

Table (14): Risk of genotype frequency of *TCF7L2*-rs7903146C>T among the OT2DM and OND populations



95%CI	NNT	RR	OR	ON D	OT2D M	Total	Genotype
34.861 (Harm) to ∞ to 3.474(Benefit)	7.716 (Benefit)	0.669 3	0.304 4	29	16	45	CC
3.744 (Harm) to ∞ to 20.301 (Benefit)	9.18 (Harm)	1.386 7	2.767 9	14	25	39	CT
2.2664 (Harm) to ∞ to 4.322 (Benefit)	13.889 (Harm)	1.219 5	2.097 6	2	4	6	TT
-	-	0.000 1	0.000 1	p-value			
-	-	0.159 4 to 2.024	1.441 to 4.887	95%CI			

Concerning the allele frequency of the *TCF7L2* gene, the findings reported a significant elevation ($p <$) in percentage and risks (OR, RR) of T allele (64.44%, 1.6008, 1.1948, respectively) when compared to C allele (48.81%, 0.5261, 0.837, respectively) in the OT2DM population as well as when compared to C (51.19%) and T (35.56%) alleles in OND individuals (Tables 15, 16).

Table (15): Allele frequency of *TCF7L2*-rs7903146C>T among the OT2DM and OND populations

95%CI	p-value	OND	OT2DM	Total	Allele
-34.88 to 65.12	0.0859	43 (51.19%)	41 (48.81%)	84	C
133.5 to 233.5	0.0231	16 (35.56%)	29 (64.44%)	45	T



-	-	0.0437	0.0237	p-value
-	-	55.92 to 142.7	42.67 to 155.9	95%CI

Table (16): Risk of Allele frequency of *TCF7L2*-rs7903146C>T among the OT2DM and OND populations

95%CI	NNT	RR	OR	OND	OT2DM	Total	Allele
13.68 (Harm) to ∞ to 4.978 (Benefit)	15.651 (Benefit)	0.837	0.5261	43	41	84	C
4.978 (Harm) to ∞ to 13.68 (Benefit)	15.651 (Harm)	1.1948	1.6008	16	29	45	T
-	-	0.0001	0.0001	p-value			
-	-	1.257 to 3.289	5.764 to 7.891	95%CI			

Discussion

Several genes have been the focus of significant research in the past 10 years, because they may play a role in regulating insulin signaling pathways and, therefore, be responsible for an individual's susceptibility to T2DM in particular, in an obese population. In the current study, *IRS1* rs1801278G>A revealed higher frequency of GA and AA genotype and a significantly lower frequency of GG genotype in the OT2DM group indicating that the A allele (Arg972 variant) of the *IRS1* gene is crucial in enhancing T2DM susceptibility among obese individuals. Our results were similar to the findings of other international (Tang et al., 2015) and national (Mudhaffer and Hassan, 2025) who found that *IRS1*- rs1801278 polymorphism was associated with increased risk of T2DM, but were not found to be associated with insulin resistance and other related metabolic parameters in overweight



and obese individuals with T2DM in other studies (Htwe et al., 20221; Rasool et al., 2022; Shen et al., 2024). A few evidences suggest that substitution of glycine with arginine at codon 972 could change the structure of IRS1 protein, which will inhibit the interaction with key downstream signaling molecules like PI3K and AKT and thus disrupt insulin signaling pathway and contribute to insulin resistance (Khalid et al., 2021; Pei et al., 2022; Báez et al., 2024). Further studies also noted that the amino acid change in the *IRS1* gene caused by the rs1801278 polymorphism may compromise insulin downstream signaling pathways, leading to insulin resistance (Niyasti et al., 2022; Luo et al., 2023; Sarvestani et al., 2023; Mudhaffer and Hassan, 2025). Islam et al. (2024) noted that the G>A transition of the genetic variant of *IRS1*, rs1801278, has been associated with changes in insulin sensitivity and glucose homeostasis, suggesting that further research in this field is warranted to identify targeted strategies for personalized risk assessment and treatment. Further, the interaction of this polymorphism with environmental risk factors like obesity provides insights into the mechanism by which diabetes develops in at-risk individuals (Gupta et al., 2024). Taken together, the last reports show that the variant *IRS1* rs1801278 is a plausible and clinically relevant risk factor for T2DM, specifically in the genetically susceptible and obese population (Danyarova et al., 2026; Hryniewicka et al., 2026; Pal et al., 2026).

In this study, analysis of the *KCNJ11*-rs5219C>T polymorphism gene detected that the frequency of CT genotype was significantly higher than the CC and TT in OT2DM and OND populations with marked increasing the percentage and risk of T allele compared to C allele. These results indicated that the polymorphism was a possible genetic risk factor for the disease in this population. The finding is consistent with the previous and recent studies reporting importance of the *KCNJ11* gene in regulation of insulin secretion and its polymorphisms association with susceptibility to T2DM among different populations (Phani et al., 2014; Haghvirdizadeh et al., 2015; Ageeva et al., 2024; Pati et al., 2025). This effect of *KCNJ11* gene might be attributed to its role in encoding and synthesis of Kir6.2 proteins that act as a



fundamental component in ATP-sensitive potassium channel in pancreatic beta cells (Ramteke et al., 2024).

The results of this study showed that the percentage of GC and CC genotypes were apparently higher than GG genotype in the OT2DM population and in the GC genotype of the OND. For allele frequency, the results were showed a significant elevation in existence and risk of C allele in comparison with those detected in G allele of OT2DM population as well as when compared to the results of the OND individuals, G and T alleles. These results were similar with that recorded by other studies concluded additionally that the G allele of the rs1801282 polymorphism confers an increased risk of obesity and hypercholesterolemia (Li et al., 2022; Rani et al., 2025). Worldwide, several previous and recent studies have examined the polymorphism in a context of OT2DM development with findings suggesting that allele frequency is notably increases in diabetic non-obese and diabetic obese patients when compared to control group (Sokkar et al., 2009; Valeeva et al., 2022). However, other previous studies concisely reviewed that this polymorphism does not relate to predisposition of metabolic disorders (Rocha et al., 2015), or offer protection to the development of other diseases like polycystic ovary syndrome (Zhang et al., 2015) and colorectal cancer (Jiang et al., 2017). The complex interplay highlights the need for a detailed understanding of the *PPARG*-rs1801282G>C polymorphism's implications in the context of lipid metabolism and adipocyte function, especially in the context of obesity and insulin sensitivity.

In our findings, there was significantly higher allelic frequencies of CT and TT genotype in the population of OT2DM than in OND, whereas, the percentage of T and the risk of T was significantly higher than C in the population of OT2DM and compared to C allele and T allele in OND population. These data were in context that reported by many studies (Assmann et al., 2014; Ding et al., 2018; Lu et al., 2025). The molecular mechanisms behind this association include increased *TCF7L2* mRNA expression in pancreatic islets of T allele carriers, which results in reduced insulin secretion, decreased incretin effects and increased production of



hepatic glucose (Bahaeldin et al., 2020). On the other hand, the relationship between the C allele of *TCF7L2*- rs7903146 and obesity is less well explored in the literature and requires further investigations for its replication in other diversified populations (Sen et al., 2025).

Conclusion

This study indicates the predominant and risk of *IRS1G>A* (rs1801278), *KCNJ11C>T* (rs5219), *PPARGG>C* (rs1801282), and *TCF7L2C>T* (-rs7903146) in OT2DM patients. This suggests that furthermore studies are necessary to investigate the roles of various genes in OT2DM, and possible utilization of such genes in diagnosis of this metabolic disorder. Also, identifying of *IRS1*, *KCNJ11*, *PPARG*, and *TCF7L2* genes in both obese and non-obese populations can help in understanding of diseases mechanism and supported the preventing healthcare strategies. As precision medicine continuously evolved, combination of genetic information with clinical and lifestyle factors could be greatly managed and reduced the burden of T2DM.

Ethical approval

This study was approved by the Scientific Committee in the Department of Biology (Collage of Science, University of Wasit).

References

1. Abdullah, A.S., and Ali, S.K. (2022). Assessment of the relationship of transcription factor 7-like 2 rs4506565 (T/A) variant with type 2 diabetes in Iraqi Arab patients. *Meta Gene*, 31, 101008. <https://doi.org/10.1016/j.mgene.2021.101008>
2. Adeerjiang, Y., Sidike, A., Gan, X. X., Li, Q. T., and Jiang, S. (2025). The role of Wnt3a/ β -catenin/TCF7L2 pathway in diabetes and cardiorenal complications. *Cardiorenal medicine*, 15(1), 72-82. <https://doi.org/10.1159/000543145>
3. Ageeva, E. S., Shramko, I. I., Kubyshkin, A. V., Fomochkina, I. I., Zhukova, A. A., Tarimov, C. O., and Zaurova, M. B. (2024). The role of genetic factors in likelihood of type 2 diabetes mellitus. *Risk Assessment in Hygiene*, (3), 167. <https://doi.org/10.21668/health.risk/2024.3.17.eng>
4. Albegali, A. A., Shahzad, M., Mahmood, S., and Ullah, M. I. (2019). Genetic association of insulin receptor substrate-1 (*IRS-1*, rs1801278) gene with insulin



- resistant of type 2 diabetes mellitus in a Pakistani population. *Molecular biology reports*, 46(6), 6065-6070. <https://doi.org/10.1007/s11033-019-05041-w>
5. Al-Shaeli, S. J. J., Ethaeb, A. M., and Al-Zaidi, E. A. N. (2022). Serological and histological evaluation of the effect of honeybee venom on pancreas and liver in diabetic mice. *Archives of Razi Institute*, 77(3), 1125. <https://doi.org/10.14202/vetworld.2022.2357-2364>
 6. Assmann, T. S., Duarte, G. C., Rheinheimer, J., Cruz, L. A., Canani, L. H., and Crispim, D. (2014). The TCF7L2 rs7903146 (C/T) polymorphism is associated with risk to type 2 diabetes mellitus in Southern-Brazil. *Arq Bras Endocrinol Metab* 58 (9), 918-925. <https://doi.org/10.1590/0004-2730000003510>
 7. Baqer, S.K., and Shwan, N.A.A. (2023). PPARG and FTO gene variants and their association with type 2 diabetes in the Kurdish population. *Passer Journal of Basic and Applied Sciences*, 5, 171-177.
 8. Blanken, C. P., Bayer, S., Buchner Carro, S., Hauner, H., and Holzapfel, C. (2025). Associations Between TCF7L2, PPARG, and KCNJ11 Genotypes and Insulin Response to an Oral Glucose Tolerance Test: A Systematic Review. *Molecular Nutrition and Food Research*, 69(3), e202400561. <https://doi.org/10.1002/mnfr.202400561>
 9. Chandrasekaran, P., and Weiskirchen, R. (2024). The role of obesity in type 2 diabetes mellitus-An overview. *International journal of molecular sciences*, 25(3), 1882. <https://doi.org/10.3390/ijms25031882>
 10. Danyarova, L., Svyatova, G., Berezina, G., Tuleutayev, R., Sultanova, B., Taigulova, A., and Karibayeva, I. (2026). Association of Genetic Polymorphisms with Gestational Diabetes in a Kazakh Population: A Case-Control Study. *Diagnostics*, 16(5), 663. <https://doi.org/10.3390/diagnostics16050663>
 11. Ding, W., Xu, L., Zhang, L., Han, Z., Jiang, Q., Wang, Z., and Jin, S. (2018). Meta-analysis of association between TCF7L2 polymorphism rs7903146 and type 2 diabetes mellitus. *BMC medical genetics*, 19(1), 38. <https://doi.org/10.1186/s12881-018-0553-5>
 12. Dracheva, K., Surtsukova, M. G., Pobozheva, I., Anisimova, K. A., Hamid, Z. M., Balandov, S. G., and Miroshnikova, V. (2024). Expression profile of IL2RA, FOXP3, PPARG, IL6, IL10, LRRC32 AND GATA3 genes in adipose tissue of patients with obesity and type 2 diabetes mellitus. *Atherosclerosis*, 395. <https://doi.org/10.1016/j.atherosclerosis.2024.117867>
 13. Gharban, H.A., Sray, A.H., and Essa, I.M. (2024). Serological prevalence of anti-Fasciola hepatica antibodies in sheep. *Egyptian Journal of Veterinary Sciences*, 55(6), 1583-1590. <https://doi.org/10.21608/ejvs.2024.257463.1742>
 14. Giannopoulos, C. K., Tzima, I. G., Tentolouris, N. K., and Vasileiadis, I. A. (2023). Common pathogenetic pathways of non-alcoholic fatty liver disease and



- type 2 diabetes mellitus. *Current diabetes reviews*, 19(9), 96-114. <https://doi.org/10.2174/1573399819666230216112032>
15. Gupta, M. K., Gouda, G., and Vadde, R. (2024). Relation between obesity and type 2 diabetes: evolutionary insights, perspectives and controversies. *Current Obesity Reports*, 13(3), 475-495. <https://doi.org/10.1007/s13679-024-00572-1>
 16. Haghvirdizadeh, P., Mohamed, Z., Abdullah, N. A., Haghvirdizadeh, P., Haerian, M. S., and Haerian, B. S. (2015). KCNJ11: genetic polymorphisms and risk of diabetes mellitus. *Journal of diabetes research*, 2015(1), 908152. <https://doi.org/10.1155/2015/908152>
 17. Haider, R. (2023). Unraveling Insulin's Mechanisms: A Comprehensive Analysis. *Chemistry and Drugs Studies*, 2(1), 2. <https://doi.org/10.58396/cds020102>
 18. Hryniewicka, J., Buczyńska-Backiel, A., Zbucka-Krętowska, M., Krętowski, A. J., and Szelachowska, M. (2026). Molecular Genetics of β -Cell Compensation in Gestational Diabetes Mellitus: Insights from CDKAL1, SLC30A8 and HHEX. *International Journal of Molecular Sciences*, 27(2), 1121. <https://doi.org/10.3390/ijms27021121>
 19. Htwe, T. N., Thein, O. M., Hmone, S. W., and Thandar, M. (2021). Prevalence of insulin receptor substrate-1 gene (G972R) polymorphism, insulin resistance, and determination of β -cell function among overweight and obese persons with type 2 diabetes mellitus. *Journal of the ASEAN Federation of Endocrine Societies*, 36(1), 25. <https://doi.org/10.15605/jafes.036.01.03>
 20. Islam, M. S., Romy, T. M., Ahmed, P., Keya, U. R., Ehsan, F., Al Shahriar, M. S., and Islam, K. A. (2024). Impact of IRS1 (rs1801276) Gene Polymorphism on Type-2 Diabetes Mellitus in Bangladeshi Patients. *Healthmed J Pharm Sci*, 2(2), 7-12. <https://doi.org/10.64461/hjps.v02i02y24.02>
 21. Jiang, J., Xie, Z., Guo, J., Wang, Y., Liu, C., Zhang, S., and Chen, Y. (2017). Association of PPAR γ rs 1801282 C> G polymorphism with risk of colorectal cancer: From a case-control study to a meta-analysis. *Oncotarget*, 8(59), 100558. <https://doi.org/10.18632/oncotarget.20138>
 22. Jo, E. (2024). *Role of Autophagy in PPAR-induced Changes in Lipid Metabolism in the Liver* (Doctoral dissertation, RMIT University). <https://doi.org/10.25439/rmt.27582093>
 23. Khalid, M., Alkaabi, J., Khan, M. A., and Adem, A. (2021). Insulin signal transduction perturbations in insulin resistance. *International journal of molecular sciences*, 22(16), 8590. <https://doi.org/10.3390/ijms22168590>
 24. Kumar, A. (2024). *Functional and genetic approaches to decipher novel roles of Src homology region 2 domain-containing phosphatase-1 (SHP1) in physiology and metabolism* Thèse (Doctoral dissertation, Laval University). <https://dx.doi.org/10.13140/RG.2.2.12113.13923>



25. Li, S., He, C., Nie, H., Pang, Q., Wang, R., Zeng, Z., and Song, Y. (2022). G allele of the rs1801282 polymorphism in PPAR γ gene confers an increased risk of obesity and hypercholesterolemia, While T allele of the rs3856806 polymorphism displays a protective role against dyslipidemia: A systematic review and meta-analysis. *Frontiers in endocrinology*, 13, 919087. <https://doi.org/10.3389/fendo.2022.919087>
26. Lu, Y. C., Yu, T. H., Hsuan, C. F., Hsu, C. C., Hung, W. C., Wang, C. P., and Lee, T. L. (2025). Association of TCF7L2 rs7903146 (C/T) Polymorphism with Type 2 Diabetes Mellitus in a Chinese Population: Clinical Characteristics and Ethnic Context. *Diagnostics*, 15(16), 2110. <https://doi.org/10.3390/diagnostics15162110>
27. Luo, Q., Ling, Z., Huang, X., and Zuo, Y. (2023). Association of IRS-1 and IRS-2 polymorphisms with predisposition to type-2 diabetes (T2D): A meta-analysis and trial sequential analysis. *Nucleosides, Nucleotides and Nucleic Acids*, 42(11), 837-851. <https://doi.org/10.1080/15257770.2023.2211122>
28. Báez, B.A., Ayala, G., Pedroza-Saavedra, A., González-Sánchez, H. M., and Chihu Ampan, L. (2024). Phosphorylation codes in IRS-1 and IRS-2 are associated with the activation/inhibition of insulin canonical signaling pathways. *Current issues in molecular biology*, 46(1), 634-649. <https://doi.org/10.3390/cimb46010041>
29. Merrins, M. J., and Kibbey, R. G. (2024). Glucose regulation of β -cell KATP channels: it is time for a new model!. *Diabetes*, 73(6), 856-863. <https://doi.org/10.2337/dbi23-0032>
30. Mudhaffer, N. Q., and Hassan, I. A. A. (2025). Expression and polymorphisms of the IRS1 gene as related with the risk of type 2 diabetes mellitus in Iraqi patients. *International Journal of Endocrinology (Ukraine)*, 21(7), 708-712. <https://doi.org/10.22141/2224-0721.21.7.2025.1636>
31. Nasr, F. M. E., Gaber, O. A., Mohamed, E. A., and Eldeeb, A. S. (2024). Possible correlations between KCNJ11 and risk of diabetes mellitus. *Zagazig University Medical Journal*, 30(8.1), 4191-4199. <https://doi.org/10.21608/zumj.2024.267527.3157>
32. Niyasti, P., Saberi, A., Hatamyain, H., Ajamian, F., Ghorbani Shirkouhi, S., Mirzanejad, L., and Andalib, S. (2022). Association of insulin receptor substrate-1 gene polymorphism (rs1801278) with Alzheimer's disease. *Journal of Alzheimer's Disease Reports*, 6(1), 73-80. <https://doi.org/10.3233/adr-210060>
33. Oluwamodupe, C., and Babalola, O. O. (2024). Ion channels and regulation of insulin secretion in beta-cells. *Current Molecular Biology Reports*, 10(4), 65-77. <https://doi.org/10.1007/s40610-024-00162-z>



34. Pal, S., Firdous, S. M., and Obi, E. A. (2026). Genetic and Epigenetic Insights into Gestational Diabetes Mellitus: Implications for Early Diagnosis and Management. *Precision Nutrition and Endocrine Health*, 1-27. <https://doi.org/10.1201/9781998511877-1>
35. Pati, B., Jastroch, M., and Bal, N. C. (2025). Is Predisposition to T2D Impacted by Polymorphisms in Genes Involved in Insulin Signaling and Cellular Bioenergetics?. *Acta Physiologica*, 241(12), e70122. <https://doi.org/10.1111/apha.70122>
36. Pei, J., Wang, B., and Wang, D. (2022). Current studies on molecular mechanisms of insulin resistance. *Journal of Diabetes Research*, 2022(1), 1863429. <https://doi.org/10.1155/2022/1863429>
37. Phani, N. M., Guddattu, V., Bellampalli, R., Seenappa, V., Adhikari, P., Nagri, S. K., and Rai, P. S. (2014). Population specific impact of genetic variants in KCNJ11 gene to type 2 diabetes: a case-control and meta-analysis study. *PLoS One*, 9(9), e107021. <https://doi.org/10.1371/journal.pone.0107021>
38. Rana, N. S., Vishvakarma, N. K., Sonkar, S. C., and Beg, M. M. A. (2026). Diabetes: A comprehensive review of the Indian landscape in contrast with global trends. *World Journal of Diabetes*, 17(2), 110701. <https://doi.org/10.4239/wjd.v17.i2.110701>
39. Rani, C. A. L. J. A., Gowda, R. N., Muniswamy, V., Srinivas, A., Prashant, A., Vishwanath, P., and Ramachandra, S. C. (2025). Association of PPARG gene variants with obesity in South Indian young adults: a cross-sectional study. *BMJ Connections Clinical Genetics and Genomics*, 2(1). <https://doi.org/10.1136/bmjccgg-2025-000034>
40. Rasool, S. U. A., Nabi, M., Ashraf, S., and Amin, S. (2022). Insulin receptor substrate 1 Gly972Arg (rs1801278) polymorphism is associated with obesity and insulin resistance in Kashmiri women with polycystic ovary syndrome. *Genes*, 13(8), 1463. <https://doi.org/10.3390/genes13081463>
41. Reddy, S., Maddhuri, S., Nallari, P., Ananthapur, V., Kalyani, S., Krishna, M., and Patibandala, S. (2021). Association of ABCC8 and KCNJ11 gene variants with type 1 diabetes in south Indians. *Egyptian Journal of Medical Human Genetics*, 22(1), 27. <https://doi.org/10.1186/s43042-021-00149-w>
42. Rob, A., Hoque, A., Asaduzzaman, M. M., Khaton, M. A. A., Khalil, R., Thomas, D., and Chowdhury, T. A. (2025). The global challenges of type 2 diabetes. *Bangladesh Journal of Medicine*, 36(2), 92-98. <https://doi.org/10.3329/bjm.v36i2.78406>
43. Rocha, R. M., Barra, G. B., Rosa, É. C. C. C., Garcia, É. C., Amato, A. A., and Azevedo, M. F. (2015). Prevalence of the rs1801282 single nucleotide polymorphism of the PPARG gene in patients with metabolic syndrome. *Archives*



- of *Endocrinology and Metabolism*, 59(4), 297-302. <https://doi.org/10.1590/2359-3997000000086>
44. Salamah, J., Cheeran, E., Beck, B., Ahmad, Z., and Lee, B. K. (2026). TCF7L2 is essential for the differentiation and invasive function of human extravillous trophoblast. *Cellular and Molecular Life Sciences*, 83(1), 30. <https://doi.org/10.1007/s00018-025-05991-4>
45. Sami, A., Javed, A., Ozsahin, D. U., Ozsahin, I., Muhammad, K., and Waheed, Y. (2025). Genetics of diabetes and its complications: a comprehensive review. *Diabetology and Metabolic Syndrome*, 17(1), 185. <https://doi.org/10.1186/s13098-025-01748-y>
46. Sarvestani, F. A., Shayan, T. K., Abdolmaleki, A., and Asadi, A. (2023). Polymorphisms in insulin pathway genes and cancer risk. *Basic and Clinical Cancer Research*. <https://doi.org/10.18502/bccr.v13i4.14403>
47. Sen, P., Alam, S. S., Jahan, I., Saha, P., Akter, F., and Shill, L. C. (2025). Association of the TCF7L2 rs7903146 variant with type 2 diabetes mellitus and related biomarkers: a systematic review. *BMJ Nutrition, Prevention and Health*, 8(2). <https://doi.org/10.1136/bmjnph-2025-001205>
48. Shen, L., Liu, J., Zhao, X., Wang, A., and Hu, X. (2024). Association between insulin receptor substrate 1 gene polymorphism rs1801278 and gestational diabetes mellitus: an updated meta-analysis. *Diabetology and Metabolic Syndrome*, 16(1), 62. <https://doi.org/10.1186/s13098-024-01289-w>
49. Singh, P., Tripathy, D. B., and Kumar, G. (2026). Pharmacogenomics-Guided therapeutics in type 2 diabetes: Mechanisms, drug Targets, and precision medicine perspectives. *Journal of Diabetes and Metabolic Disorders*, 25(1), 56. <https://doi.org/10.1007/s40200-025-01843-x>
50. Sokkar, S., El-Sharnouby, J. A., Helmy, A., El-Bendary, A., Ahmad, L. S., and Okasha, K. (2009). Role of peroxisome proliferator-activated receptor gamma2 (PPAR- γ 2) gene polymorphism in type 2 diabetes mellitus. *European Journal of General Medicine*, 6(2):78-86. <https://doi.org/10.29333/ejgm/82645>
51. Szablewski, L. (2024). Changes in cells associated with insulin resistance. *International journal of molecular sciences*, 25(4), 2397. <https://doi.org/10.3390/ijms25042397>
52. Tang, W., Wang, Y., Jiang, H., Liu, C., Dong, C., Chen, S., and Gu, H. (2015). Insulin receptor substrate-1 (IRS-1) rs1801278G> A polymorphism is associated with polycystic ovary syndrome susceptibility: a meta-analysis. *International Journal of Clinical and Experimental Medicine*, 8(10), 17451. <https://doi.org/10.37506/mlu.v21i2.147451>
53. Tian, S., Zhao, H., and Song, H. (2024). Shared signaling pathways and targeted therapy by natural bioactive compounds for obesity and type 2 diabetes. *Critical*



- Reviews in Food Science and Nutrition*, 64(15), 5039-5056.
<https://doi.org/10.1080/10408398.2022.2148090>
54. Valeeva, F. V., Medvedeva, M. S., Khasanova, K. B., Valeeva, E. V., Kiseleva, T. A., Egorova, E. S., and Ahmetov, I. I. (2022). Association of gene polymorphisms with body weight changes in prediabetic patients. *Molecular biology reports*, 49(6), 4217-4224. <https://doi.org/10.1007/s11033-022-07254-y>
55. Veerabathiran, R., Sivakumar, S., Kalarani, I. B., and Mohammed, V. (2023). A review of genes associated with obesity susceptibility: findings from association studies. *Journal of Health Science and Medical Research*, 41(6), 2023959. <https://doi.org/10.31584/jhsmr.2023959>
56. Yang, X., and Yang, Y. (2025). The crucial role of potassium ion channels in diabetes mellitus and its complications: A review. *Channels*, 19(1), 2531949. <https://doi.org/10.1080/19336950.2025.2531949>
57. Yang, Z., Danzeng, A., Liu, Q., Zeng, C., Xu, L., Mo, J., and Zhang, B. (2024). The role of nuclear receptors in the pathogenesis and treatment of non-alcoholic fatty liver disease. *International Journal of Biological Sciences*, 20(1), 113. <https://doi.org/10.7150/ijbs.87305>
58. Younus, A. H., and Al-Faisal, A. H. M. (2024). Correlation between TCF7L2 gene expression and certain biochemical parameters in type 2 diabetes mellitus. *Journal of Taibah University Medical Sciences*, 19(3), 575-584. <https://doi.org/10.1016/j.jtumed.2024.04.005>
59. Zhang, S., Wang, Y., Jiang, H., Liu, C., Sun, B., Chen, S., and Tang, W. (2015). Peroxisome proliferator-activated receptor gamma rs1801282 C> G polymorphism is associated with polycystic ovary syndrome susceptibility: a meta-analysis involving 7,069 subjects. *International Journal of Clinical and Experimental Medicine*, 8(10), 17418. <https://doi.org/1940-5901/IJCEM0014639>

JOBS



مجلة العلوم الأساسية
Journal of Basic Science



Print -ISSN 2306-5249

Online-ISSN 2791-3279

العدد الثالث والأربعون

٢٠٢٦ م / ١٤٤٧ هـ



مجلة العلوم الأساسية
للعلوم التربوية والنفسية وطرائق التدريس للعلوم الأساسية